Gold Nest Capital is a life science venture capital firm, specialised in healthcare and biotechnology. Based in Singapore, Japan and Germany, the firm brings together a cross-border team of highly qualified professionals, with a strong scientific, finance and business expertise. Gold Nest Capital is launching a new expansion capital fund that primarily invests in Europe and Asia. Our new fund will focus on cell and gene therapies, next-generation biologics, and their enabling technologies such as advanced manufacturing, bioinformatics, and AI. The fund is expecting to launch in Q4 2023.